Bradley J. Monk

Gynecologic Oncology | Oncology

1309 N Flagler Dr
West Palm Beach, FL 33401

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 349 publications

Corrigendum to 'Endometriosis and ovarian cancer risk' [Gynecologic Oncology 209C (2026) 88-98].

Corrigendum to 'Endometriosis and ovarian cancer risk' [Gynecologic Oncology 209C (2026) 88-98].

Journal: Gynecologic oncology

Published: June 02, 2026

Understanding Cancer Clinical Trial Participation in Rural Communities: A Qualitative Focus Group Study.

Understanding Cancer Clinical Trial Participation in Rural Communities: A Qualitative Focus Group Study.

Journal: Psycho-oncology

Published: April 23, 2026

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Journal: Gynecologic oncology

Published: April 12, 2026

Immune checkpoint inhibition in ovarian cancer: Reassessing its potential.

Immune checkpoint inhibition in ovarian cancer: Reassessing its potential.

Journal: Gynecologic oncology

Published: March 03, 2026

Endometriosis and ovarian cancer risk.

Endometriosis and ovarian cancer risk.

Journal: Gynecologic oncology

Published: February 20, 2026

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

Journal: Lancet (London, England)

Published: February 10, 2026

Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.

Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.

Journal: Lancet (London, England)

Published: February 04, 2026

Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.

Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.

Journal: Gynecologic oncology

Published: February 02, 2026

Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer.

Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer.

Journal: JCO precision oncology

Published: January 14, 2026

Industry payments to U.S. gynecologic oncologists: Gender, geographic, and therapeutic trends.

Industry payments to U.S. gynecologic oncologists: Gender, geographic, and therapeutic trends.

Journal: Gynecologic oncology

Published: December 23, 2025

The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201.

The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201.

Journal: Future oncology (London, England)

Published: December 12, 2025

Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer.

Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 31, 2025

Showing 1-12 of 349

Last Updated: 09/26/2026